Nusinersen,
does it really help with Improved motor-milestone attainment and event-free survival without death or permanent ventilation in spinal muscular atrophy?
research showsNusinersen is rated B because randomized sham-controlled trials demonstrated motor-milestone response and survival without death or permanent ventilation in infantile-onset spinal muscular atrophy, plus improved motor scores in later-onset disease. ENDEAR stopped early for clear efficacy; in final analysis, motor-milestone response was 51% versus 0% and the hazard ratio for death or permanent ventilation was 0.53. The rare single indication, early trial termination, and remaining long-term hard-endpoint uncertainty keep the grade below A.
ads claimMotor response should not be described as normal development or cure for every patient. Response varies with onset, timing of treatment, baseline function, and respiratory status, and ongoing multidisciplinary support remains necessary.
Useful facts when choosing a product
- Nusinersen is administered intrathecally with loading doses followed by maintenance dosing every four months.
- Lumbar-puncture-related headache, back pain, bleeding, and infection can occur; platelet count, coagulation testing, and renal monitoring are performed before dosing.
- Korean National Health Insurance coverage for Spinraza follows separate eligibility, prior-review, and periodic response-assessment rules; current HIRA criteria and individual review must be checked, and reimbursement is not evidence for the efficacy grade.
What the research actually shows
ENDEAR randomized 121 infants with 5q SMA beginning before six months of age in a 2:1 ratio to nusinersen or sham lumbar puncture. A prespecified interim analysis showed motor-milestone response of 41% versus 0%, prompting early termination; final analysis was 51% versus 0%. Risk of death or permanent ventilation was lower, and final-analysis overall survival was also significantly improved (hazard ratio 0.37, 95% CI 0.18-0.77). CHERISH randomized 126 participants with later-onset SMA and found a 5.9-point treatment difference in 15-month HFMSE change and a higher proportion improving by at least three points.
Why this is classified as B (79)
Randomized benefit was repeated across ENDEAR motor milestones and death-or-permanent-ventilation event-free survival and CHERISH later-onset motor scores. Rare single-indication scope, early termination, and limited long-term hard endpoints give B with 79 points. Lumbar-puncture, platelet, renal, and Korean reimbursement issues are assessed separately.
Counterpoint. Earlier treatment is generally more favorable, making rapid genetic diagnosis important, but respiratory, nutritional, orthopedic, and rehabilitation care remain necessary.
Rejudgment record. Cross-check applied — Assigned B after accepting ENDEAR motor-milestone and death-or-permanent-ventilation event-free-survival benefit and CHERISH later-onset motor-score benefit, while accounting for a rare single indication, interim-analysis stopping, and limited long-term hard endpoints
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Attainment of motor-function milestones | B | Final ENDEAR response rates were 51% versus 0%. |
| Improved survival without death or permanent ventilation | B | The ENDEAR composite had HR 0.53, with limitations from early stopping and limited long-term follow-up. |
| Improved motor scores in later-onset SMA | B | The 15-month HFMSE between-group difference in CHERISH was 5.9 points. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Finkel RS et al. ENDEAR. 2017 | Phase 3 randomized double-blind sham-controlled trial | 121 | Funded by Biogen and Ionis Pharmaceuticals | HINE-2 motor-milestone response and death or permanent ventilation | Final motor-milestone response was 51% versus 0%; death or permanent ventilation had HR 0.53 (95% CI 0.32 to 0.89). | Pivotal infantile-onset motor and event-free-survival evidence |
| Mercuri E et al. CHERISH. 2018 | Phase 3 randomized double-blind sham-controlled trial | 126 | Funded by Biogen and Ionis Pharmaceuticals | Change in HFMSE motor-function score at 15 months | HFMSE changed by +4.0 versus -1.9, a 5.9-point difference (95% CI 3.7 to 8.1). | Replicated randomized evidence in a distinct clinical phenotype |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-23).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-23 · Corrections: none
Cite this verdict
[Chamgap] Nusinersen x improved motor milestones and event-free survival in spinal muscular atrophy — Evidence Grade B·79. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/general/nusinersen-spinal-muscular-atrophy-motor-milestones-event-free-survival/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.